Excited to share 👇
“A major limitation of hemophilia A gene therapy is progressive loss of expression. Here the authors demonstrate that low-level expression of a gain-of-function factor VIII variant may safely restore normal hemostasis and permit durability of expression.”
Happy #InternationalWomensDay
In 1975, Barbara C. Furie helped found what is now known as the Division of Hemostasis and Thrombosis at BIDMC. Our Division would not be what it is today without Barbara C. Furie!
Two of the main research articles in this week's @NEJM are on Gene Therapy for #hemophilia A and B. There is an excellent editorial by Lindsey George on the FVIII Gene Therapy paper. I wonder why the journal did not ask her to comment on both papers.
It was a great pleasure to visit my dear friend Jorge @DipaolaJorge Laboratory at Washington University in St. Louis. #ADAMTS13 finally meets VWF at place where they originally came from.
We’re back for Day 2 at #ASH22! Happening Now: Dr. Anna Sternberg presents her team's abstract No. 398 titled: “Inhibiting Activated Protein C Cleavage of Factor VIII for Hemophilia a Gene Therapy.”
Congratulations to Sean Quinn, a postdoc in my group, for receiving the Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis. Great work, team! #ASH22@CHOP_Research
Several NIH funded postdoctoral positions are available in Majumder’s Lab in the department of Interdisciplinary Oncology at LSUHSC. Majumder’s lab use in vivo and in vitro models to investigate coagulation mechanisms in health and disease. Pl send ur CV to [email protected]